- Mydecine Innovations Group (MYCO) has submitted an application to list its common shares on the NASDAQ
- Following this application, Mydecine said it expects to file a Form 20-F Registration Statement with the United States Securities and Exchange Commission
- Mydecine Chair and CEO Josh Bartch said he believes the company is entering an accelerated growth phase
- Acceptance for listing the company’s shares is subject to approval based on several factors including satisfaction of minimum listing requirements for the NASDAQ Capital Market
- Mydecine Innovations Group closed at C$0.50 per share
Mydecine Innovations Group (MYCO) has submitted an application to list its common shares on the NASDAQ.
Following this application, Mydecine said it expects to file a Form 20-F Registration Statement with the United States Securities and Exchange Commission.
Mydecine Chair and CEO Josh Bartch said he believes the company is entering an accelerated growth phase and the timing could not be better for listing its shares to NASDAQ.
“This listing is intended to open the investment opportunity to a larger and more diverse pool of investors and help create greater shareholder value. A listing on the NASDAQ Capital Market is a natural progression for the company and our shareholders,” Bartch said.
Acceptance for listing the company’s shares is subject to approval based on several factors including satisfaction of minimum listing requirements for the NASDAQ Capital Market.
The company intends to satisfy all of the applicable listing requirements, however, there is no assurance that its application will be approved.
During the NASDAQ review process, the company’s common stock will continue to trade in Canada on the CSE under its current symbol, MYCO and on the OTC under the symbol, MYCOF.
The company has hired Ellenoff Grossman & Schole LLP as its US legal counsel to oversee the process of the NASDAQ listing.
Mydecine Innovations Group is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality.
The company’s medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems.
Mydecine Innovations Group closed at C$0.50 per share.